Mylan N.V. (NASDAQ:MYL) and collaboration partner Fujifilm Kyowa Kirin Biologics Co., Ltd. (OTCPK:FUJIF) announce the FDA nod for Hulio (adalimumab-fkjp), a biosimilar to AbbVie’s (NYSE:ABBV) top seller Humira.
Per Mylan’s July 2018 license agreement with AbbVie, it will be able to launch Hulio in the U.S. in July 2023.
Humira generated $14.9B in sales for AbbVie in 2019.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.